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ABSTRACT

Aging of the brain is the leading risk factor for neurodegenerative diseases and brain
cancers and has deleterious effects on brain functions. It follows that attempts to reverse the
aging process may be therapeutically valuable. Neural stem cells (NSC) have been shown to play
a critical role in maintaining brain functions, and their number is severely decreased with age.
The development of senescence-like characteristics and declining functions in NSCs have been
proposed to be responsible for brain aging and tumorigenesis. MS-818 is a pyrrolopyrimidine
that has been shown to increase the NSC population and reverse the decline of behavioral
function in aged rodent models. While MS-818 has demonstrated such benefits, the mechanism
by which it affects particular pathways of biological age in NSCs is not yet known.
Understanding how MS-818 relates to the molecular mechanisms underlying cellular aging may
help accelerate the development of anti-aging therapies for neurodegenerative diseases and
cancer. This study attempts to elucidate the mechanism of action of MS-818 on NSCs using an in
vitro accelerated-aging model produced by Hydroxyurea (HU) treatment. Our analysis of NSC
population size post-MS-818 exposure supports the idea that MS-818 treatment can increase
NSC proliferation. qPCR analysis of aging-related genes revealed HU treatment produced a
trend of increased p16 and Il-6 and decreased Lamin B1 relative expression, supporting the
notion that HU treatment can induce senescence in NSCs. MS-818 treatment alone also produced
notable trends for targets including BRCA1. In addition, MS-818 treatment post-HU exposure
appeared to influence the relative expression of targets, including PGC1a and Lamin B1. Such
MS-818 treatment produced similarly noteworthy trends for the expression of genes including
ii

PGC1a, Lamin B1, BRCA1, RPTOR, and Il-6, whether in media containing 2.5% or 7.5%
serum. These results indicate that MS-818 may have influenced some aging-related pathways.
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INTRODUCTION

Aging of the Brain

With biological aging of the brain comes a higher rate of cancer, neurodegeneration, and
other severe ailments that produce poor prognosis and suffering 1. Outside illnesses, an aged
brain can suffer from declining functionality1, which can worsen one's quality of life and inhibit
productivity to society. Aging is complex and neither fully understood nor characterized; in
general, however, biological aging could be considered as the accumulation of harmful changes
over time, leading to detrimental changes to function 2,3.

Macroscopic Changes in the Brain

Although not comprehensively characterized, various behavioral, neuronal, and physical
changes in the brain occur at higher rates and degrees in older individuals 1,4. Such alterations can
have direct connections to the quality of life and well-being of the elderly. These changes have
no elucidated mechanism, but proposed hypotheses link them to age-related alterations at the
cellular level1,4. The effects of age on the brain are broad and controversial, but some notable and
less contended changes are described below.
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Behavioral

There is a general decline in brain function with aging, and this is seen clearly through a
reduction in memory. Studies have shown that declarative memory pertaining to recalling
specific past events (episodic memory)5, declines after middle age6. A decline in episodic
memory due to age parallels what occurs in Alzheimer's disease (AD), a neurogenerative disease
correlated with age7. Long-term memory, in general, has been seen to decline with age, caused
by decreased executive function, and working memory 8. Working memory is short-term active
memory important in executive function 9, and its decline leads to limitations in the active usage
of information. This could lead to deficiencies in a wide variety of cognitive tasks that demand
conscious effort, severely impacting day-to-day activites10. Beyond memory, general brain
performance declines with age, demonstrated by worsened reaction times, attention, processing
speed, and sensory functionality11,12. Some of these declines may be associated with the
deterioration of executive function, which is used in day-to-day tasks ranging from reasoning to
the processing of novel information13.

Neuronal/physical

Speculative connections have been made between the aging-associated declines in mental
behavior and underlying changes to the brain's physical characteristics 4. Brain volume shrinks
with age, its weight decreasing at a rate of 5% each decade after 40 and even faster after 70 14,15.
2

This atrophy has been proposed to be due to neuron death, which also alters brain function 1,4.
Studies have shown that the prefrontal cortex is most heavily affected 15, which is significant
considering the prefrontal cortex plays a vital role in executive function 16. Age-related brain
atrophy affects both the grey and white matter, with studies showing an increase in frontal lobe
white matter lesions (WML) and demyelination with age after middle age 17. Such WMLs have
been associated with neurodegenerative diseases, irregular metabolism, and worsened executive
function18. Deterioration in the frontal lobe may lead to symmetrical activation in both
hemispheres in an attempt to compensate, leading to hemispheric asymmetry reduction in older
adults (HAROLD) 19. Changes in other factors such as hormones or neurotransmitters may also
play a role in brain aging. The levels of dopamine and serotonin diminish with age and are
associated with declines in episodic memory, motor performance, plasticity, and
neurogenesis20,21. Hormones such as brain-derived neurotrophic factor also decrease with age
and may be related to reductions in cognitive performance20. Sex hormones, like estrogen, also
tend to decrease with age, possibly leading to further declines in brain function 22.

Current Therapies

To date, there is no cure for the aging process; nevertheless, treatments such as hormone
replacement therapy (HRT) and lifestyle changes have shown potential success in protecting
against some age-associated deteriorations. While still inconclusive, HRT, particularly estrogen
replacement therapy in postmenopausal women, has seen mixed success in improving the
3

cognitive ability of elderly women23. Women taking the therapy performed better on memory
tests of visual and verbal stimuli when confounding variables, such as education and health, were
controlled23. Similar therapies aimed at increasing local sex hormone levels in animal models
showed mixed success for neuroprotection. Still, they revealed that factors such as route of
delivery, the timing of administration, and age of the subject, play significant roles in
effictiveness24. Experimental findings make it evident that sex hormones can positively benefit
neuronal health and overall brain function25,26. However, other studies have shown that only
verbal fluency improved with HRT, leaving overall cognitive ability unaffected 27. Other
troubling studies revealed an increased risk for breast cancer for users of HRT 28.
Without pharmaceuticals, modest lifestyle changes have been shown to elicit
neuroprotective or even regenerative effects on the aged brain and cognition. Dietary changes,
notably caloric restriction (CR), may delay the aging process and decrease the risk for
neurodegenerative diseases29,30. CR has proved successful in increasing synaptic plasticity,
preserving brain physiology, and suppressing age-related changes to gene expression 30–32.
Aerobic exercise has been shown to prevent age-associated brain atrophy and improve executive
function in aged adults ranging from 60 to 75 33,34. Studies have shown that having aged rodents
moved to enriched environments can increase neurogenesis in the dentate gyrus, indicating that
novel environmental stimulus can be enough to affect the brain positvely 35.
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Aging at the Molecular Level
Along with deterioration of behavior, cognition, and neural/physical characteristics of the
brain with age, differential gene expression and modification to molecular patterns also occur for
aged cells. This progressive aging and deterioration of brain cells have been proposed to be
responsible for some of the described macroscopic age-related changes 4. However, measuring
age or senescence, "stable arrest of the cell cycle coupled to stereotyped phenotypic changes" 36,
in cells is multifaceted and complex. While many molecules are involved in aging at the cellular
level, this study will focus on a restricted set of molecular markers/pathways.

Senescence Associated Secretory Phenotype (SASP)

As cells age, there is an increase in cellular stress, notably oxidative stress produced from
free radical reactions37,38. In response to this stress, cellular senescence and stress response
pathways can be induced, one of which may be the secretion of pro-inflammatory cytokines and
chemokines38. In doing so, these cells may express the senescence-associated secretory
phenotype (SASP), in which pro-inflammatory factors, proteinases, growth factors, and other
components are released by senescent cells39,40. The expression of the SASP in senescent cells
may create a local pro-inflammatory environment that could damage neighboring cells/tissue and
induce them to become senescent and also express a SASP 41.
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Similarly, the aged brain suffers from increased oxidative stress, among other stress
response indicators, and chronic inflammation produced by dystrophic microglia and increased
pro-inflammatory factors42,43. Astrocytes, in particular, express changes indicative of the SASP
with age, including increased expression of cytokines such as interleukin (IL) 6 (IL-6) and IL1𝛽, increased levels of glial fibrillary acidic protein (GFAP) and vimentin, and age-related
changes to cellular structures38.

Cell Cycle Arrest

Cellular Senescence in stem cells is characterized partially by cell cycle arrest despite the
presence of growth-stimulation, and this inability to proliferate can lead to improper cell/tissue
functions44. It has been proposed that aged cells enter senescence, and thereby halt cell cycle
progression, as a stress response to prevent cells from becoming cancerous after DNA damage or
a deleterious consequence of the loss in regenerative capability 45.
The p16INK4a/Rb and p53/p21CIP1 tumor suppressor pathways have been identified to be
important in preventing cells from continuing through the cell cycle 46. The cyclin-dependent
kinase (CDK) inhibitors p16 and p21 are upregulated in senescent cells, including NSCs 47, and
can cause cell cycle arrest even in the presence of growth factors 48.
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mTOR Pathway Activity

The mechanistic target of rapamycin (mTOR) pathway is, in short, a network of signals
that processes various extra/intracellular signals and directs metabolic responses resulting in
effects such as growth, proliferation, inflammation, and apoptosis 49. The mTOR pathway is
highly implicated in the aging process50, as its inhibition can extend lifespan in organisms 51. The
phenotypical changes experienced by senescent cells, including the SASP, involve pathways
regulated by mTOR52. mTOR has also been proposed to be hyperactive in senescent cells, and
studies have shown that activation of the pathway can move locked quiescent cells, which
experience cell cycle arrest due to both CDK inhibitors and a lack of growth factors, into
senescence53.
A component of the mTOR complex 1 (mTORC1), the regulatory protein associated with
mTOR (RPTOR or Raptor), has been noted to be down-regulated in members of long-living
families and older members of the same family 54. Additionally, RPTOR mRNA expression has
been observed to decrease with Rapamycin treatment, indicating RPTOR expression decreases
with mTOR pathway inhibition55.

Telomere Length

Telomeres are DNA and protein structures on the ends of chromosomes that preserve
genomic information by preventing degradation and undesirable fusions 56. The DNA portion of
7

telomeres constitutes repeats of the 'TTAGGG' sequence, and shortening of these repeats has
been observed to be highly associated with aging and senescence 57. A small portion of the
telomere is lost in normal cell division, which can eventually lead to senescence or apoptosis of
the cell57,58. Telomerase is a ribonucleoprotein enzyme complex containing a telomerase reverse
transcriptase (TERT) catalytic subunit and is important in maintaining telomere length by
synthesizing additional DNA repeats59.
The downregulation of TERT has been linked to aging in the brain, as decreased
telomerase activity correlates with hippocampus shrinkage in early aging. TERT overexpression
results in neuroprotection and the reversal of certain aging processes. TERT normal expression
contributes to the self-renewal, viability, and maintenance of NSCs 59. Telomere length and
telomerase activity have been suggested to impact the ability of stem cells to regenerate tissue,
and telomere length shortening has been considered a marker and mechanism for age-related
conditions56,59,60. Along with biological aging, critically short telomeres have been associated
with certain pathological aging stages in neurodegenerative diseases. The findings suggest that
telomere shortening is accelerated in neurodegenerative diseases, and a critically short telomere
may be a synergistic factor for pathogenesis61.
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Mitochondrial Dysfunction

Mitochondrial dysfunction, a decline in ATP output as a result of declined respiratory
chain function, increases with age and cellular senescence 47,62. It has been suggested that this is
due to mutations or other accumulated errors in the mitochondrial DNA (mtDNA) 62 caused by
replication or reactive oxygen species (ROS)62,63. The dysfunctional mitochondria may then elicit
a senescence response similar to that of the SASP64, produce ROS that causes age-related
changes in cells63, and produce other deleterious effects.
Studies have suggested that mitochondrial dysfunction plays a role in the decline of stem
cells due to age65. In the brain, mitochondrial dysfunction has been noted in hippocampal cells
that had undergone cellular senescence66. The peroxisome-proliferator-activated receptor gamma
coactivator-1 (PGC) family of transcription coactivators have been identified as master
transcriptional regulators of mitochondrial proteins and play a key role in mitochondrial
physiology and metabolism67. Particularly, the family member PGC-1a has been well studied and
observed to coordinate gene expression in response to environmental stimuli, and its expression
is closely tied to the mitochondrial content 68. Regarding aging, PGC-1a expression has been
observed to decrease with age and neurodegeneration, in correlation with mitochondrial
dysfunction68. Further, PGC-1a overexpression resulted in a neuroprotective effect on neurons
against oxidative stress69.CR, which has been implicated with anti-aging phenomena, has been
shown to inhibit age-related PGC-1a downregulation 70.
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DNA Damage

A dominant theory regarding a cause of aging is the accumulation of DNA mutation and
damage, leading to lower molecular fidelity and the aging phenotype 71. The increase in DNA
damage could be caused by various factors such as ROS, a decrease or abnormalities in DNA
repair mechanisms, or the shortening of telomeres 71. The resulting genomic instability, altered
gene expression, and reduction of molecular fidelity could then lead to the expression of the
senescence phenotype71.
Stem cells demand a high level of genomic integrity to maintain differentiation and selfrenewal and have been noted to be highly proficient in DNA repair 72. The transcription of DNA
repair genes such as BRCA1 and BLM decreases with senescence, and the decrease of only
BRCA1 or BLM was found to be enough to cause DNA damage 73. BRCA1 is further noteworthy
considering its overexpression in NSCs can reduce oxidative stress and apoptosis 74.

Alterations to Nuclear Lamina

With cellular senescence, cells change their morphology, particularly their nucleus 75. The
changes in nuclear arrangements can lead to gene repression and gene regulation, which may
impact the senescence phenotype and aging75. The structure and stability of the nucleus are
dependent partially on the nuclear envelope, which is composed of the lamina, intermediate
filaments that are important to structure75. Studies have shown that lamin B1 mRNA
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downregulation is highly associated with senescence and aging in fibroblasts 75 and is especially
impactful for the central nervous system (CNS)76. Lamin B1 expression has also been noted in
NSCs and is believed to play a role in development77.

Decreased Susceptibility to Apoptosis

The chronic stress associated with age may lead to the expression of senescent
phenotypes, and these senescent cells may attempt to defend against such stressors through
apoptotic resistance78. However, this may be disadvantageous to the organism as the
accumulation of senescent cells due to a lack of apoptosis may lead to deleterious consequences
to nearby tissue41. The actions of p53, in particular, are likely involved in either developing
resistance to apoptosis or suppressing factors related to apoptotic sensitivity 79.
The downregulation of pro-apoptotic proteins could provide senescent cells with their
apoptotic resistance. The Bcl-2 protein family plays an important role in apoptosis and includes
the major pro-apoptotic protein, Bax. Studies have observed the downregulation of Bax protein
and mRNA, thereby inhibiting apoptosis, when cells are induced into a senescent state 80,81. This
downregulation has been proposed to be part of a compensatory mechanism to prevent extensive
cell death80.
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Hydroxyurea as a Stress-Inducer to Produce an NSC Aging Model

HU was initially used as an antineoplastic drug for its ability to disrupt cell cycle
progression, but at mild doses has been used to induce senescence 80,82. HU's mechanism of
action is through the inhibition of ribonucleotide reductase (RR), an important enzyme for the
synthesis of deoxyribonucleotides. A reduction in available deoxyribonucleotides leads to the
inhibition of DNA synthesis for both nuclear and mitochondrial DNA and disruption of S-phase
progression. Importantly, this leads to an increase in DSBs at the replication fork during DNA
synthesis, leading to DNA damage and cellular stress/dysfunction. The inhibitory effect of HU
on RR is reversible, and after removal of HU, the RR returns to its active state. However, the
DNA damage may persist83.
Studies on mouse postnatal NSCs have found that an 8mM dosage of HU for 12 hours
leads to persistent DNA damage and induction of senescence. This study found an increase in
various senescence markers, including ROS, p16, p21, p53, yH2AX foci, senescence-associatedBeta-Galactosidase, etc., that remained even 36 hours post-HU exposure 80. HU treatment has
been further validated to produce an NSC aging model when applied to human Embryonic Stem
cell-derived NSCs82. This study found that 8mM HU exposure for 16 hours produces longlasting (over 36 hours after HU exposure) yH2AX activation and cellular senescence while
minimizing cell death82.
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Pyrrolopyrimidine Compound (MS-818)

MS-818, or 2-piperadino-6-methyl-5-oxo-5,6-dihydro(7H)pyrrolo[2,3-d]pyrimidine
maleate, is a pyrrolopyrimidine compound that was shown to increase endogenous NSC
proliferation by nearly seven fold84–86. Studies have shown that MS-818 increases hNSC
metabolic activity, and thereby proliferation, in vitro in a dose-dependent manner86. MS-818 also
increases the metabolism of MSCs but with an EC50 30 times that needed for hNSCs, indicating
a preferential effect for NSCs86. When used in aged/young rodents in vivo, MS-818 was observed
to increase cell populations in the Dentate Gyrus (DG) and subventricular zone (SVZ), regions
where adult NSCs are known to reside86. Beyond proliferation, treatment with MS-818 promoted
neuronal migration of endogenous NSCs into the white matter of aged rodents, indicated by
doublecortin. Taken together, this indicates MS-818 has beneficial effects on neurogenesis and
increasing adult NSC populations86. The effects on brain function were assessed in mice using a
Rotarod test, and MS-818 was found to improve rotarod running times in cognitively impaired
mice and had little impact on control mice, suggesting no overt detrimental motor side-effects
are produced86. This is further supported by toxicology testing, which found that MS-818 had no
toxic effects at physiological doses, and Ames testing, which revealed no detected mutagenic
effects86. Thus, MS-818 shows a remarkable ability for repairing brain function through the
increase of endogenous NSC populations, neurogenesis, and neuronal migration, processes that
are often compromised with age84–86.
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Aging of Stem Cells

Significant to the process of aging is the deleterious changes associated with stem cells,
as described in the "stem cell theory of aging". In summary, this theory holds that with age, there
is a loss in the ability for stem cell populations in the body to continue to replenish tissues with
sufficient differentiated cell types/populations capable of maintaining tissue/organ function 87. In
the brain, studies have shown that some age-associated declines in brain function can be linked
to a decrease in NSC proliferation and differentiation capabilities coupled with increased NSC
senescence88. NSC populations in the aging brain decrease in number, particularly in the SVZ
and DG, likely due to the decline in self-renewal/proliferation, decreased neurogenesis, increased
gliogenesis, and senescence89–91. The cause of this age-associated decline is not fully understood.
However, it has been suggested that mechanisms involving pathways described previously may
be involved, such as those related to DNA damage, telomere shortening, mitochondrial
dysfunction, and epigenetic changes, among others 87.
As a potential therapy for the detrimental effects of aging, previous studies attempted to
reverse the biological age in stem cell populations by targeting pathways that likely cause the
dysfunction. However, such strategies have shown only mixed success 92. Reversal of the
decreased proliferation and neurogenesis of aging NSC populations through MS-818 has
demonstrated success in improving brain function. However, the mechanism by which this is
done, in terms of aging, has not been investigated 86.
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OBJECTIVES

1. To determine the optimal dosage of MS-818 treatment on Fetal human NSCs (F-HNSCs)
to maximize proliferation in either 2.5% or 7.5% serum.
2. To affirm the viability of HU exposure (8mM for 16 hours) to produce an aging model in
F-HNSCs, through qPCR analysis of several senescence-related biomarkers.
3. To determine the effect of MS-818 treatment on several age-related pathways in an aging
model of F-HNSCs, through qPCR analysis of several age and senescence-related
biomarkers.
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HYPOTHESIS

An important characteristic of the aging brain is the decline in NSC populations. Such
declines could be attributed to senescence-like characteristics of aged NSCs, including decreased
proliferation. MS-818 has been previously identified to increase adult NSC populations by
increasing endogenous NSC proliferation, in contrast to the normal aged NSC phenotype.
However, the mechanism by which MS-818 alters NSC proliferation and metabolism is
unknown.
We hypothesize that MS-818's mechanism of action involves influencing one or more
aging-related pathways in a therapeutic manner. Namely, if an aged model of F-HNSCs is treated
with an optimized concentration of MS-818, then the mRNA expression of one or more
biomarkers related to aging/senescence will change in an inverse manner to that of aged FHNSCs alone. This study will also consider whether a difference in serum concentration of either
2.5% or 7.5% will influence the effects MS-818 has on such age-related biomarkers in aged FHNSCs.
Therefore, it has been proposed to utilize HU to induce a senescent phenotype in FHNSCs and observe changes in mRNA expression of several age-related biomarkers through
qPCR after treatment with MS-818.
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METHODS

F-HNSC Cell Culture
F-HNSCs were purchased from Lonza as Fetal-derived human neural progenitor cells and
grown in suspension cultures. The cells were cultured in ‘HNSC’ media composed of EGF
(20ng/ml), bFGF (20ng/ml), Heparin 5000U (0.5U/ml), 1% Antibiotics/Antimycotics
(Pen./Strep.) and 2% B27 stock mixed in DMEM/F12. The F-HNSCs were expanded prior to
experimentation in T-75 suspension flasks, incubated at 37ºC with 5% CO2, and ~50% of the
media was changed every 3-4 days. F-HNSCs naturally formed neurospheres that were
dissociated every 1-2 weeks, depending on neurosphere size, via mechanical or enzymatic
processes. Before experimentation, F-HNSCs were singularized for counting and downstream
applications using Accutase.
Proliferation/Population Size Assessment
F-HNSCs were seeded in 12-well plates at a seeding density of 500,000 cells/well, with
1.5ml serum-containing media. The media used for experimentation was composed of either
2.5% serum and 25% HNSC media (2.5% serum media) or 7.5% serum and 66% HNSC media
(7.5% serum media). The remainder of the media was DMEM/F12. After a 24-hour rest period
post-seeding, each well was given an additional 500ul of appropriate serum media containing
MS-818 at 4X concentration. The solution was mixed by lightly shaking the plate, resulting in
final MS-818 concentrations of 1nM, 10nM, and 100nM. Each concentration was given to 3
17

separate wells. After an additional 72 hours with MS-818, the suspension cells in neurospheres,
and any that had spontaneously differentiated and adhered, were singularized using Accutase.
The singularized cells from each well were concentrated into 150uL or 250uL of media, and a
10uL aliquot was used to determine the cell population size using a hemocytometer. An Ordinary
One-Way ANOVA, with Dunn's multiple comparison test was performed on relative population
sizes using Prism7.

HU and MS-818 Treatment Procedure and Timeline
F-HNSCs were seeded in 6-well plates at a seeding density of 1,000,000 cells/well, with
1.5ml of HNSC media. After a 24-hour rest period post-seeding, the appropriate cells
experienced HU exposure in a similar methodology to that optimized by Daniele 82. Each well
was given 500ul of HU at 4X concentration (32mM) in HNSC media. The solution was then
mixed by lightly shaking the plate to produce a final HU concentration of 8mM. After 16 hours
of exposure to 8mM HU, the cells from each well were spun at 300 rcf for 5 min. and
resuspended in 1.5ml of the appropriate serum media (2.5% or 7.5%). After being washed with
HNSC media, the cells were then re-seeded into their original well. After a brief (4-5 hour) rest
period, the appropriate wells were given 500ul of MS-818 at 4X concentration (40nM) in
2.5%/7.5% serum media. After 72 hours of MS-818 treatment, the cells were processed for
downstream mRNA analysis.
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RNA extraction, and cDNA synthesis

F-HNSCs were treated as described and were prepared for RNA extraction. Suspension
cells were gathered with the spent media and spun at 300 rcf for 5 min, and washed with ice-cold
1X PBS. F-HNSCs that had adhered were lightly washed with 1X PBS and given 333ul TRIzol
Reagent per well and incubated at room temperature for 5 min. Afterward, the TRIzol in
triplicate wells (subject to identical conditions) were pooled together, resulting in 1ml of TRIzol
reagent. This 1ml TRIzol was used to resuspend and subsequently lyse the pellet of cells that
corresponded to the triplicate wells. According to the manufacturer's protocol with an in-column
DNase I treatment, the RNA from the lysed cells and TRIzol was then extracted using the Directzol RNA miniprep kit Zymo Research93. RNA concentration and purity were determined using a
NanoDrop 8000 Spectrophotometer. Purified RNA was then used to generate complementary
DNA using the SuperScript IV Reverse Transcriptase enzyme and associated reagents/buffer
according to the manufacturer's protocol94.

Real-Time Quantitative PCR Analysis
Real-time quantitative PCR was performed using the QuantStudio 7 Flex Real-Time PCR
system on the following targets: PGC1a, TERT, p16, Bax, Il-6, Lamin B1, RPTOR, BRCA1,
p53, and B-actin. Such targets were assessed in F-HNSCs that underwent described experimental
treatments in 2.5% serum media. Of the listed targets, those which experienced notable trends of
19

differential expression between groups were then evaluated in F-HNSCs treated in 7.5% serum
media. qPCR was performed in triplicates with a total volume of 20ul per reaction. Each reaction
contained 100ng of cDNA, synthesized as previously described, 10uL of SYBR Green PCR
Master Mix95, 300nM forward and reverse primer concentration, and molecular grade water. The
qPCR thermal method began with a 95ºC hold stage for 20s followed by 40 cycles of 1s at 95ºC
and 20s at 60ºC or 59ºC. Primers were purchased from Eurofins Genomics and are listed with
associated information in Table 1.
After the PCR stage, a Melt Curve was produced with a thermal method beginning with
15s at 95ºC, then 60s at 60ºC, and ending with 15s at 95ºC. Melt Curves revealed that each
primer produced a single PCR product. Relative mRNA expression was determined by the 2 -ΔΔCt
method using the corresponding F-HNSC control as the reference sample (set to 1.0) and B-actin
as the reference gene.
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RESULTS & DISCUSSION

Optimization of MS-818 Dosage

F-HNSCs, in either 2.5% or 7.5% serum media, were given 1nM, 10nM or 100nM
concentrations of MS-818 for 72 hours as previously described. Assessment of F-HNSC count
using a hemocytometer revealed a trend of increased NSCs with MS-818 treatment. The increase
in cell number was statistically significant (α = 0.05) for only the 10nM MS-818 treatment in
either serum condition (Figure 1). In addition, NSC numbers had an increasing trend for all MS818 concentrations tested compared to the control. However, the 1nM and 100nM MS-818
treatment appeared to produce a reduced pro-proliferative effect compared to the 10nM MS-818
treatment (Figure 1). These results affirm prior studies that have found MS-818 to increase NSC
populations in vivo and indicate 10nM MS-818 as the optimal concentration to increase
proliferation in F-HNSCs for this study.
Interestingly, MS-818 appeared to have increased proliferation to a greater extent in FHNSCs when in 7.5% serum media in comparison to 2.5%. At 10nM MS818, the concentration
which produced the most significant increase, F-HNSC population size increased by over 1.5fold in 7.5% serum media while only increasing by ~1.25 fold in 2.5% serum media (Figure 1).
Such observations may indicate that MS-818 is better able to exert its pro-proliferative effect
when at 7.5% serum as opposed to 2.5%, but further testing of the phenomena would need to be
conducted.
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Affirming the Viability of Hydroxyurea Treatment to Produce an Aging Model in F-HNSCs

The qPCR analysis of F-HNSCs treated with HU in 2.5% serum media suggests a
difference in mRNA expression of p16, Il-6, and BRCA1 compared to the control. Minor trends
of differential expression are also present for RPTOR and Lamin B1(Figure 2). Similar trends of
potentially differential mRNA expression were seen in the 7.5% serum condition where
appropriate (Figure 3). The elevated expression of p16 suggests an inhibition of cell-cycle
progression, an indication of cellular senescence likely produced by the DNA damage caused by
HU. This data is consistent with previous studies that found elevated p16 in mouse NSCs treated
with HU80. Additionally, the trend of decreased Lamin B1expression is also consistent with the
senescent phenotype and may indicate dysregulation of the nuclear membrane structural integrity
(Figure 2,3). There was a relatively drastic trend of increased Il-6 mRNA in both the 2.5% and
7.5% serum conditions (Figure 2,3). This may indicate that F-HNSCs have an activated SASP
and a pro-inflammatory state consistent with senescence when exposed to HU.
Oddly, there was an apparent lack of or unexpected differential expression of p53, Bax,
and BRCA1 in HU-treated NSCs in the 2.5% serum condition when compared to prior studies 80.
There was no apparent difference in p53 expression between HU-treated NSCs and control,
despite increased p53 expression being associated with cell cycle arrest and senescence (Figure
2). While prior studies have identified upregulation of p53 after HU exposure 80,82, this was from
cells 36 hours after HU treatment, while mRNA in this study was collected over 72 hours post22

HU treatment. This delay may have allowed some cell-cycle regulatory proteins, like p53, to
return to normal levels, while others, like p16, remain upregulated. BRCA1 mRNA had a trend
of drastic upregulation, over 3-fold, over 72 hours post-HU exposure (Figure 2). Although this
data contrasts with prior studies80, the upregulation may have been produced as a compensatory
mechanism to the HU-induced DNA damage after a significant period of recovery. Bax is a
major pro-apoptotic protein, and its expression was observed to decrease in senescent cells,
including NSCs treated with HU80. However, we observed no apparent change in Bax expression
with HU treatment (Figure 2). This data may indicate that after prolonged rest post-HU
treatment, the NSCs lacked the apoptotic resistance supplied by a decrease in Bax expression.
Yet, this observation may not necessarily indicate an unchanged or increased propensity for
apoptosis, as the anti-apoptotic proteins like Bcl-2 were not measured, and a ratio between
Bax/Bcl-2 expressions cannot be established.
Additionally, RPTOR mRNA displayed a minor decreasing trend of expression in FHNSCs treated with HU in either serum condition (Figure 2,3). While the relationship between
RPTOR expression and aging is less clearly defined than other targets, RPTOR mRNA
expression was shown to decrease with mTOR inhibition55. Thus, it may indicate that the mTOR
pathway, or portions of the pathway, are disrupted or inhibited by HU exposure. Such
dysregulation may influence cell cycle progression and metabolism, with potential links to the
senescence phenotype.
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The Effect of MS-818 Treatment on an F-HNSC Aging Model

To explore potential pathways by which MS-818 influences aged F-HNSCs, we assessed
the mRNA expression of F-HNSCs in 2.5% serum media targeting nine genes related to aging,
using B-actin as a reference. Of these nine targets, five with a notable trend of differential
expression between HU and MS-818 treated F-HNSCs and the control were assessed again with
groups in 7.5% serum media. qPCR analysis revealed a minor trend of differential expression
between F-HNSCs treated with HU and MS-818 or MS-818 alone and their appropriate controls
for the targets: PGC1a, Lamin B, BRCA1, TERT, p16, Il-6, Bax, and RPTOR (Figure 2,3).
PGC1a is a master regulator of mitochondrial transcription, physiology, and health.
Increased expression of PGC1a has been observed to produce a neuroprotective effect as
well67,69. In this study, we found MS-818 produced a trend of increased mRNA expression of
PGC1a in HU-aged NSCs with respect to the HU-treated control in either serum condition
(Figure 2,3). This data may indicate that MS-818 has a stimulatory or otherwise therapeutic
effect on mitochondrial function for aged NSCs. A minor decreasing trend was observed in
PGC1a mRNA due to MS-818 treatment on non-aged NSCs (Figure 2,3). This may indicate that
the apparent upregulation is specific to MS-818 treatment on poor health/senescence cells and
that MS-818 may influence the mitochondria differently in non-aged NSCs.
Lamin B1 is an important structural protein for the nuclear lamina and has been observed
to decrease with senescence75. We observed Lamin B1expression to have a decreasing trend
upon HU treatment, consistent with the senescence phenotype. However, upon MS-818
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treatment, HU-aged NSCs recovered Lamin B1expression to almost that of the non-treated
control in 2.5% serum media (Figure 2). In the 7.5% serum media, this trend was also present but
to a far lesser degree (Figure 3). The apparent upregulation of Lamin B1may indicate a reversal
of the senescence phenotype with regards to the structural integrity of the nuclear envelope.
Additionally, without prior HU exposure, MS-818 treatment appeared to produce a trend of
increased Lamin B1 in 2.5% serum media while producing a trend of decreasing Lamin B1 in
7.5% serum media (Figure 2,3). Such discrepancy may indicate a potential difference in the
therapeutic capacity of MS-818 dependent on serum concentration. However, this trend would
need to be validated in future studies to identify the relationship better.
RPTOR mRNA expression has been linked to mTOR pathway activity which plays an
important role in proliferation, metabolism, apoptosis, etc. In addition, mTOR pathway inhibition
has been observed to increase lifespan and prevent stem cell senescence 96. We observed an
increasing trend in RPTOR mRNA expression between F-HNSCs treated with HU and MS-818
and those treated with HU only in the 2.5% serum media (Figure 2). The light upregulation of
RPTOR may be restorative regarding the senescence-phenotype, considering the mTOR pathway
is involved with cellular proliferation and metabolism. Also, this apparent upregulation brings
RPTOR expression closer to that of the non-aged control. However, considering mTOR's link
with aging, the therapeutic plausibility of MS-818's influence on the mTOR pathway requires
further study to be determined. In addition, this restorative trend was absent under 7.5% serum
conditions (Figure 3), suggesting this relationship may only appear in a low nutrient
environment. In both serum conditions, MS-818 alone did not appear to alter RPTOR mRNA
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expression. These data suggest that MS-818 may influence RPTOR with some specificity
towards senescent/stressed NSCs and variable effects based on environmental conditions.
p16 is a CDK inhibitor that prevents progression through the cell cycle, and Bax is a
major pro-apoptotic protein. For both, MS-818 appeared to exacerbate the trends in differential
expression produced by HU treatment (Figure 2,3). While p16 was expected to increase with
senescence due to an arrest of the cell cycle, F-HNSCs treated with MS-818 and HU also
experienced an increasing trend in p16 expression (Figure 2,3). This seems to suggest that MS818 further strengthens the cell-cycle arrest experienced by HU-induced senescent NSCs. This
same trend appeared to a lesser degree when cells were in 7.5% serum media. The increase in
p16 runs counter to the increase in NSC proliferation from MS-818 treatment observed by prior
studies on aged in vivo models86,97 and warrants further investigation and validation into the
mechanism by which MS-818 influences p16. However, under non-aged conditions, p16
expression appeared to have a decreasing trend for NSCs treated with MS-818 alone compared
under 7.5% serum conditions (Figure 3). This data matches our finding that MS-818 increases
proliferation in NSCs in 7.5% serum media (Figure 1), perhaps indicating that MS-818
influences p16 differentially under the presence of HU and environmental conditions.
Bax was expected to decrease in expression in response to HU as a compensatory
mechanism to resist apoptosis. However, we observed a minor increasing trend in Bax
expression with HU, and a slightly greater upregulatory trend in Bax expression in F-HNSCs
treated with HU and MS-818 (Figure 2). This upregulation of Bax by MS-818 is absent when FHNSCs are not treated with HU. These data may suggest that MS-818 promotes a pro-apoptotic
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state with specificity to senescent/stressed NSCs. Although without establishing a ratio between
Bax and Bcl-2, a clear understanding of the apoptotic state cannot be determined.
Il-6 is a pro-inflammatory cytokine with increased expression in cells expressing the
SASP. However, Il-6 has also been shown to be important for NSC proliferation and the
maintenance of NSC populations98. We observed a trend of increased Il-6 expression in NSCs
treated with MS-818 and HU compared to the HU control in both serum conditions (Figure 2,3).
Such an increase may indicate an increase in expression of the SASP, or perhaps this increase is
in relation to Il-6's role in NSC proliferation and self-renewal. While the latter would be more
consistent with data indicating MS-818 increases proliferation, further study would be necessary
to elucidate the relationship. This increase was not consistently seen with NSCs treated with MS818 alone, between the 2.5% and 7.5% serum conditions (Figure 2,3). This could indicate MS818 influences Il-6 differently in different serum conditions, although further validation would
be needed.
TERT is the catalytic subunit of Telomerase and has been observed to have decreased
expression in aged cells. We found that F-HNSCs in 2.5% serum media treated with MS-818 and
HU or MS-818 alone exhibited a trend of decreased TERT expression with respect to the
respective controls (Figure 2). This suggests MS-818 may interact with the telomere synthesis
machinery in cells that are both non-senescent and senescent. However, considering the
important role of Telomerase in maintaining stem cells, this minor decreasing trend falls in
contrast to the proliferation results (Figure 1). Thus, further investigation would be needed to

27

validate the downregulation and elucidate how MS-818 influences TERT while promoting
proliferation.
BRCA1 is an important DNA repair protein and was found to be downregulated post-HU
treatment80. BRCA1 overexpression has also been observed to produce a neuroprotective effect
against oxidative stress74. We discovered that MS-818 treatment without HU produced a trend of
increased mRNA expression of BRCA1 when compared to the non-treated control in 2.5%
serum media (Figure 2). In the same serum media, MS-818 treatment post-HU exposure
appeared to produce a trend of increased BRCA1 expression compared to cells exposed to HU
alone, although the trend was only slight (Figure 2). This suggests that MS-818 may increase
BRCA1 mRNA expression under non-senescent/stressed conditions and to a lesser extent in
senescent conditions. This trend in BRCA1 regulation may produce a neuroprotective effect on
the NSCs by potentially increasing the DNA repair protein levels. While further study would be
needed to determine how MS-818 increases BRCA1 and if this produces a neuroprotective
effect, the data indicate MS-818 treatment may be sufficient to produce an increase in BRCA1.
Therefore, the results of this study suggest that MS-818 influences several age-related
biomarkers/pathways when applied to non-aged and HU-induced senescent F-HNSCs.
Potentially therapeutic differential expression of PGC1a, Lamin B, BRCA1, and perhaps Il-6 and
RPTOR was observed for F-HNSCs treated with HU and MS-818 or MS-818 alone compared to
F-HNSCs treated with HU alone or the non-treated control (Figure 2,3). However, the
relationship between Il-6 and RPTOR expression and the senescence phenotype of NSCs is less
clear. In addition, p16, TERT, and Bax expression also exhibited trends of differential
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expression, although in contrast to what was expected from findings that MS-818 increases NSC
proliferation (Figure 1,2,3). We also found that at serum concentrations of either 2.5% or 7.5%,
the expression of certain targets was altered in F-HNSCs of various experimental conditions.
However, differences were minor for the most part (Figure 2,3). These findings indicate potential
pathways to explore in further studies to elucidate the mechanism by which MS-818 influences
aging.

29

TABLES & FIGURES

Figure 1: Fold Change of F-HNSC Population Size After 72-hour MS-818 Treatment
F-HNSCs were treated with 1nM, 10nM and 100nM MS-818. After 72 hours, cells were singularized and counted using a
hemocytometer (three 4x4 squares counted). Fold change is depicted and values were normalized to the total cell count of the
control F-HNSC group. Error bars represent Standard Deviation. Ordinary One-Way ANOVA, with Dunn’s multiple
comparison test, *p < 0.05. N=6.
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Figure 2: Quantitative PCR Analysis of Age-Related Target Expression – 2.5% Serum Media
Relative expression of PGC1a, TERT, p16, Bax, Il-6, p53, BRCA1, Lamin B1and RPTOR in F-HNSCs treated with MS818 (10nM), HU (8mM), or MS-818 (10nM) and HU (8mM) in 2.5% Serum media, as previously described. Fold change
depicted, normalized to F-HNSC control group and the reference gene B-actin using the 2-ΔΔCt method. N=1.
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Figure 3: Quantitative PCR Analysis of Age-Related Target Expression – 7.5% Serum Media
Relative expression of p16, PGC1a, RPTOR, Lamin B1and Il-6 in F-HNSCs treated with MS-818 (10nM), HU
(8mM), or MS-818 (10nM) and HU (8mM) in 7.5% Serum media, as previously described. Fold change depicted,
normalized to F-HNSC control group and the reference gene B-actin using the 2-ΔΔCt method. N=1.
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Table 1: Primers Used for qPCR Analysis
Target

Primer Sequence (5'-3')

Il-6

Forward

GGTACATCCTCGACGGCATCT

Reverse

GTGCCTCTTTGCTGCTTTCAC

Forward

ACTGATGGAGTCCGAAATGC

Reverse

TCATCCGATCCTTCATCCTC

Forward

CATTTTTCCTGCGCGTCAT

Reverse

GCGACATCCCTGCGTTCT

Forward

AGGCTAGTCCTTCCTCCATGC

Reverse

GTTGGCTGGTGCCAGTAAGAG

Forward

CTTTCATCATTCACCCTTGGC

Reverse

ACATCTGCCCAATTGCATGG

Lamin
B1

Forward

AATCGTTGTCAGAGCCTTAC

Reverse

CCTTATACAGCCTCACTTGG

BAX

Forward

CCCGAGAGGTCTTTTTCCGAG

Reverse

CCAGCCCATGATGGTTCTGAT

Forward

ACCAGAGGCAGTAACCAT

Reverse

GTAGGACCTTCGGTGACT

Forward

GTGTGGAGTATTTGGATGAC

Reverse

ATGTAGTTGTAGTGGATGGT

Forward

AGAGCTACGAGCTGCCTGAC

Reverse

AGCACTGTGTTGGCGTACAG

RPTOR
TERT
PGC1a
BRCA1

p16
p53
β-Actin

Annealing
Temp.
(°C)
60

Product
Size
(bp)
80

Accession Num.

Reference

NM_000600.5

Starkie et al.,
200199

60

170

NM_020761.3

Foster et al.,
2010100

60

78

NM_198253.3

Vallarelli et al.,
2016101

60

95

NM_001354827.2

Thau et al.,
2012102

59

100

NM_007294.4

Garcia et al.,
2005103

60

199

NM_005573.4

Idriss et al.,
2019104

60

155

NM_138761.4

Chen et al.,
2017105

60

126

NM_058195.4

Currò et al.,
2014106

60

106

NM_000546.6

Currò et al.,
2014106

60

184

NM_001101.5

Chen et al.,
2016107

List of Primers used for qPCR Analysis. Annealing temperature used in this study are indicated along with estimated
product size. Accession number for the target mRNA is indicated and a reference is provided for the primer source.
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